Interleukin Genetics Receives Notice of Allowance for United States Patent for PerioPredict® Genetic Risk Test

WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) — Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced that it has received a notice of allowance for a patent by the United States Patent and Trademark Office (USPTO) for an application covering the Company’s PerioPredict^® Genetic Risk Test. The application, entitled “Method for Determining Severity and Progression of Periodontal Disease,” has allowed claims covering methods of determining a subject’s genotype to ascertain their risk of developing severe periodontal disease and the treatment of those at risk to slow the progression of the disease.

“This allowed application forms another key component of our commercial strategy for PerioPredict,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics.  “We continue to make investments to advance the clinical utility of PerioPredict to provide caregivers useful genetic insights to manage inflammation.  This allowed application supports these investments in science and evidence to ultimately provide improved care to patients.”

The patent portfolio that forms Interleukin’s intellectual property continues to strengthen, covering both current products and those under development.  Over the past year, the following patents have issued in major markets throughout the world.

• Improved Method and Kit for Determining Severity and Progression of Periodontal Disease
  • New Zealand Granted July 2015
• Genetic Markers for Weight Management and Methods of Use Thereof
  • China Granted August 2015
  • Japan Granted January 2016
  • European Union Granted March 2016
• Genetic Predisposition to Osteoarthritis Associated Conditions
  • Australia Granted May 2015
  • Japan Granted June 2015
  • European Union Granted November 2015

“Our commitment to cutting edge science is evidenced by our success in obtaining key patents that support our product portfolio,” said Dr. Ken Kornman, Chief Scientific Officer of Interleukin Genetics. “Securing patent protection is a critical element of our ongoing product development strategy to support the long-term success of our commercial products. Strategically, we are committed to expand our intellectual property with additional key patent applications pending in the U.S. and globally.”
About PerioPredict
PerioPredict is an innovative, easy-to-use genetic test that identifies individuals with an increased risk for severe and progressive periodontitis, due to a life-long genetic predisposition to over-produce Interleukin-1 (IL-1), a key mediator of inflammation. Such individuals may benefit from enhanced dental care to prevent or treat periodontitis and thereby lower their systemic inflammatory burden. Targeted management of systemic inflammation has been shown to help manage several chronic diseases, including type 2 diabetes and coronary artery disease. The PerioPredict test is made available to employees in covered health plans under the supervision of a licensed dentist or physician, and the results provide important information to dental professionals for assessing prevention and treatment options for their patients. The PerioPredict test is run solely in Interleukin’s CLIA-certified lab in Waltham, MA.  For more information, please visit www.PerioPredict.com.
About Interleukin’s Weight Management Genetic Test
Interleukin Genetics’ Weight Management Genetic Test, sold under the Inherent Health® brand, helps take the guesswork out of finding an effective diet and exercise solution by revealing actionable steps to achieve weight goals based on genetics. The test determines whether a low fat, low carbohydrate or balanced diet may be best, and whether normal or vigorous exercise is needed to most efficiently lose existing body fat. The test provides new information beyond traditional assessments so that nutritional intake and fitness routines can be tailored for improved, sustainable results. This test identifies five Single Nucleotide Polymorphisms (SNPs) in four human genes: fatty acid binding protein 2 (FABP2); adrenergic receptor beta 2 (ADRB2 – two SNPs); adrenergic receptor beta 3 (ADRB3); and peroxisome proliferator-activated receptor gamma (PPAR-γ). These markers are involved in certain physiological pathways relating to body weight. Certain patterns of markers are associated with differential response to certain diet and exercise regimens. Additional information on Interleukin’s Weight Management Genetic Test is available at https://www.inherenthealth.com/our-tests/weight-management.aspx.

About Osteoarthritis
The most common forms of OA involve the hand, knee, hip, and spine. The etiology of OA is multifactorial, involving both mechanical and biochemical factors. OA progression is associated with accelerated cartilage degradation leading to joint space narrowing, painful joint disruption, and functional compromise. OA disease progression is characterized by a proinflammatory gene expression pattern in cartilage and in joint synovial fluid, with a reactive increase in bone density in the subchondral bone. OA may involve a single joint or multiple joints in the same individual, with current therapy focused on pain relief, as there is no FDA-approved therapy that arrests or reverses the joint deterioration.  The OA test is currently in development at Interleukin.

About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions.  The products empower individuals and their healthcare providers to manage existing health and wellness through genetics-based insights and actionable guidance.  Interleukin Genetics leverages its research, intellectual property, and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market.  The company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels.  Interleukin Genetics’ lead products include its proprietary PerioPredict genetic test for periodontal disease and its Inherent Health® line of genetic tests.  Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvements Amendments (CLIA).  For more information, please visit www.ilgenetics.com.
Forward-Looking Statements
Certain statements contained herein are “forward-looking” statements, including, but not limited to, statements that PerioPredict offers the potential to improve outcomes for patients and ultimately to reduce long-term healthcare expenses associated with oral health and with chronic inflammatory conditions related to oral health.  Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in Interleukin’s annual report on Form 10-K for the year ended December 31, 2014, and other filings with the Securities and Exchange Commission.  Interleukin disclaims any obligation or intention to update these forward-looking statements.

Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC
(212) 915-2568
hans@lifesciadvisors.com
Media Contact:
Jennifer Moritz
Zer0 to 5ive for Interleukin Genetics
(917) 748-4006 
jmoritz@0to5.com